基于血浆可溶性尿激酶型纤溶酶原激活物受体水平的院前急诊患者病情预测风险评分模型的构建

沈亚静, 桂永清, 赵胤杰, 等. 基于血浆可溶性尿激酶型纤溶酶原激活物受体水平的院前急诊患者病情预测风险评分模型的构建[J]. 临床急诊杂志, 2023, 24(8): 412-417. doi: 10.13201/j.issn.1009-5918.2023.08.005
引用本文: 沈亚静, 桂永清, 赵胤杰, 等. 基于血浆可溶性尿激酶型纤溶酶原激活物受体水平的院前急诊患者病情预测风险评分模型的构建[J]. 临床急诊杂志, 2023, 24(8): 412-417. doi: 10.13201/j.issn.1009-5918.2023.08.005
SHEN Yajing, GUI Yongqing, ZHAO Yinjie, et al. Construction of a risk score model for prognosis in pre-hospital emergency patients based on plasma soluble urokinase plasminogen activator receptor levels[J]. J Clin Emerg, 2023, 24(8): 412-417. doi: 10.13201/j.issn.1009-5918.2023.08.005
Citation: SHEN Yajing, GUI Yongqing, ZHAO Yinjie, et al. Construction of a risk score model for prognosis in pre-hospital emergency patients based on plasma soluble urokinase plasminogen activator receptor levels[J]. J Clin Emerg, 2023, 24(8): 412-417. doi: 10.13201/j.issn.1009-5918.2023.08.005

基于血浆可溶性尿激酶型纤溶酶原激活物受体水平的院前急诊患者病情预测风险评分模型的构建

  • 基金项目:
    陆军军医大学科技创新能力提升专项项目(No:2021XJS18);重庆市卫生适宜技术推广项目任务书(No:2020jstg015)
详细信息

Construction of a risk score model for prognosis in pre-hospital emergency patients based on plasma soluble urokinase plasminogen activator receptor levels

More Information
  • 目的 研究院前急救患者的血清可溶性尿激酶型纤溶酶原激活物受体(soluble urokinase plasminogen activator receptor,suPAR)水平和变化规律,构建基于血清suPAR水平的院前急诊患者病情预测的风险评分模型。方法 选取2022年4月—2022年7月陆军军医大学第一附属医院120救护车接诊的114例患者作为研究对象,收集患者基本特征数据、生命体征及suPAR血清值,并对其进行7 d的短期随访。根据患者入院后最终是否收入重症监护室分为危重组和非危重组,比较2组间suPAR水平及其他因素的差别,应用多因素logistic回归分析院前急救患者病情预测的影响因素,根据回归方程建立logistic回归模型,并对多因素分析有意义的指标赋分建立院前急救患者病情预测的风险评分模型,采用受试者工作特征(ROC)曲线确定模型的最佳截断值并评估其应用价值。结果 危重组的suPAR血清水平、男性占比、呼吸频率、意识水平明显高于非危重组,危重组的收缩压、GCS评分低于非危重组,差异有明显统计学意义(P < 0.05)。多因素分析提示呼吸频率、收缩压、suPAR、GCS评分是院前急救患者病情的预测影响因素,其中suPAR(OR=4.808,95%CI:2.269~10.189,P < 0.05)和呼吸频率(OR=1.231,95%CI:1.015~1.493,P < 0.05)是院前急救患者病情预测的独立危险因素。logistic回归模型对院前急救患者病情预测的ROC曲线下面积为0.854(95%CI:0.783~0.925),灵敏度、特异度分别为69.1%,91.7%。建立的病情预测风险评分模型对院前急救患者病情预测的ROC曲线下面积为0.845(95%CI:0.773~0.916),灵敏度、特异度分别为66.2%,89.8%,最佳截断值为5.5分。2种模型对院前急救患者病情预测的ROC曲线下面积的比较,差异无统计学意义(Z=0.411,P>0.05)。结论 血清suPAR水平测定可作为一种独立风险因子预测院前急救患者病情的危重性,建立的风险评分模型对院前急救患者病情预测具有良好的应用价值,其分值的高低与疾病严重程度密切相关,分值为5.5分可作为区分危重和非危重的最佳截断点。
  • 加载中
  • 图 1  多变量ROC曲线预测院前急救患者的病情预测

    图 2  logistic回归模型和多指标风险评分模型对院前急救患者病情预测的ROC曲线的比较

    表 1  非危重组和危重组的基本特征和临床资料比较

    指标 非重症组
    (49例)
    重症组
    (65例)
    χ2/t P
    性别/例(%) 12.473(χ2) < 0.001
       女 28(57.0) 16(24.0)
       男 21(42.0) 49(75.0)
    年龄/岁 62.67± 15.46 61.79± 15.65 0.725(t) 0.470
    合并创伤/例(%) 0.978(χ2) 0.323
       是 7(14.0) 14(21.0)
       否 42(86.0) 51(79.0)
    下载: 导出CSV

    表 2  院前急救患者早期预后影响因素的单因素分析

    指标 非重症组(49例) 重症组(65例) χ2/t/z P
    呼吸频率/(次/min) 21(18~28) 21(0~28) -2.033(z) 0.042
    收缩压/mmHg 140±26.42 129.84±33.85 2.362(t) 0.020
    体温/℃ 36.7(36.3~39) 36.7(35~39.4) -1.119(z) 0.263
    心率/(次/min) 86(47~155) 93(55~151) 1.807(z) 0.071
    指氧饱和度/% 98(82~100) 97(68~100) -1.961(z) 0.050
    意识/分 0(0~2) 0(0~3) 3.211(z) 0.001
    GCS评分/分 15(7~15) 15(3~15) -2.953(z) 0.003
    suPAR/(ng/mL) 2.32(1.06~10.81) 3.71(1.89~31.64) -5.592(z) < 0.001
    心电图/% 1.440(χ2) 0.230
       异常 27(55.0) 43(66)
       正常 22(45.0) 50(34)
    注:1 mmHg=0.133 kPa。
    下载: 导出CSV

    表 3  院前急救患者病情预测的多因素分析

    相关因素 β SE Wald P OR 95%CI
    呼吸 0.208 0.098 4.479 0.034 1.231 1.015~1.493
    收缩压 -0.026 0.012 4.810 0.028 0.974 0.952~0.997
    suPAR 1.570 0.383 16.797 < 0.001 4.808 2.269~10.189
    GCS评分 -0.379 0.110 11.887 0.001 0.684 0.552~0.849
    下载: 导出CSV
  • [1]

    Eugen-Olsen J, Giamarellos-Bourboulis EJ. suPAR: The unspecific marker for disease presence, severity and prognosis[J]. Int J Antimicrob Agents, 2015, 46(Suppl 1): S33-34.

    [2]

    Rasmussen LJ, Ladelund S, Haupt TH, et al. Soluble urokinase plasminogen activator receptor(suPAR)in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study[J]. Emerg Med J, 2016, 33(11): 769-775. doi: 10.1136/emermed-2015-205444

    [3]

    Nasr El-Din A, Abdel-Gawad AR, Abdelgalil W, et al. Evaluation of sTREM1 and suPAR Biomarkers as Diagnostic and Prognostic Predictors in Sepsis Patients[J]. Infect Drug Resist, 2021, 14: 3495-3507. doi: 10.2147/IDR.S314237

    [4]

    Rasmussen LJH, Petersen JEV, Eugen-Olsen J. Soluble Urokinase Plasminogen Activator Receptor(suPAR)as a Biomarker of Systemic Chronic Inflammation[J]. Front Immunol, 2021, 12: 780641. doi: 10.3389/fimmu.2021.780641

    [5]

    Dowsett J, Ferkingstad E, Rasmussen LJH, et al. Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor[J]. Commun Biol, 2021, 4(1): 655. doi: 10.1038/s42003-021-02144-8

    [6]

    Schrauben SJ, Shou H, Zhang X, et al. Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort(CRIC)Study[J]. J Am Soc Nephrol, 2021, 32(1): 115-126. doi: 10.1681/ASN.2020040487

    [7]

    Frary CE, Blicher MK, Olesen T B, et al. Circulating biomarkers for long-term cardiovascular risk stratification in apparently healthy individuals from the MONICA 10 cohort[J]. Eur J Prev Cardiol, 2020, 27(6): 570-578. doi: 10.1177/2047487319885457

    [8]

    Ozdirik B, Maibier M, Scherf M, et al. Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis[J]. J Clin Med, 2022, 11(9): 2479. doi: 10.3390/jcm11092479

    [9]

    Hayek SS, Leaf DE, Samman Tahhan A, et al. Soluble Urokinase Receptor and Acute Kidney Injury[J]. N Engl J Med, 2020, 382(5): 416-426. doi: 10.1056/NEJMoa1911481

    [10]

    Velissaris D, Dimopoulos G, Parissis J, et al. Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group[J]. Infect Dis Ther, 2020, 9(3): 407-416. doi: 10.1007/s40121-020-00301-w

    [11]

    Schultz M, Rasmussen LJH, Kallemose T, et al. Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE Ⅲ trial[J]. Scand J Trauma Resusc Emerg Med, 2019, 27(1): 43. doi: 10.1186/s13049-019-0621-7

    [12]

    Isola G, Polizzi A, Alibrandi A, et al. Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor(suPAR)levels[J]. J Periodontol, 2021, 92(6): 896-906. doi: 10.1002/JPER.20-0242

    [13]

    Iversen E, Houlind MB, Kallemose T, et al. Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients[J]. Front Cell Dev Biol, 2020, 8: 339. doi: 10.3389/fcell.2020.00339

    [14]

    Rovina N, Akinosoglou K, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor(suPAR)as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia[J]. Crit Care, 2020, 24(1): 187. doi: 10.1186/s13054-020-02897-4

    [15]

    赵胤杰, 李杨, 沈亚静, 等. 血浆可溶性尿激酶型纤溶酶原激活物受体在急诊严重创伤患者病情评估中的应用研究[J]. 临床急诊杂志, 2021, 22(2): 82-86. doi: 10.13201/j.issn.1009-5918.2021.02.001 https://lcjz.whuhzzs.com/article/doi/10.13201/j.issn.1009-5918.2021.02.001

    [16]

    Haupt TH, Petersen J, Ellekilde G, et al. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study[J]. Crit Care, 2012, 16(4): R130. doi: 10.1186/cc11434

    [17]

    Rasmussen LJH, Ladelund S, Haupt TH, et al. Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor(suPAR)Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study[J]. Crit Care Med, 2018, 46(12): 1961-1968. doi: 10.1097/CCM.0000000000003441

    [18]

    Alstrup M, Meyer J, Schultz M, et al. Soluble Urokinase Plasminogen Activator Receptor(suPAR)as an Added Predictor to Existing Preoperative Risk Assessments[J]. World J Surg, 2019, 43(3): 780-790. doi: 10.1007/s00268-018-4841-1

    [19]

    Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball[J]. Dis Markers, 2009, 27(3): 157-172.

    [20]

    Ljunggren M, Castren M, Nordberg M, et al. The association between vital signs and mortality in a retrospective cohort study of an unselected emergency department population[J]. Scand J Trauma Resusc Emerg Med, 2016, 24: 21. doi: 10.1186/s13049-016-0213-8

    [21]

    Lamantia MA, Stewart PW, Platts-Mills TF, et al. Predictive value of initial triage vital signs for critically ill older adults[J]. West J Emerg Med, 2013, 14(5): 453-460. doi: 10.5811/westjem.2013.5.13411

    [22]

    牟雪枫, 时彦莹, 郭伟, 等. NEWS评分对急诊抢救室患者7 d全因死亡率预警能力的评价[J]. 临床急诊杂志, 2021, 22(4): 246-251.

  • 加载中

(2)

(3)

计量
  • 文章访问数:  585
  • PDF下载数:  108
  • 施引文献:  0
出版历程
收稿日期:  2023-04-25
刊出日期:  2023-08-10

目录